Madiha Derouazi
Directeur Technique/Scientifique/R&D chez AC IMMUNE SA
Fortune : 12 668 $ au 30/06/2024
Profil
Madiha Derouazi is the founder and current Chief Executive Officer & Director of Amal Therapeutics SA, which is founded in 2012.
She is also currently the Chief Scientific Officer at AC Immune SA, where she started in 2024.
Dr. Derouazi has a graduate degree from the Technical University of Berlin and a doctorate degree from the Swiss Federal Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AC IMMUNE SA
0,00% | 01/03/2024 | 3 175 ( 0,00% ) | 12 668 $ | 30/06/2024 |
Postes actifs de Madiha Derouazi
| Sociétés | Poste | Début |
|---|---|---|
| AC IMMUNE SA | Directeur Technique/Scientifique/R&D | 01/01/2024 |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Fondateur | 03/09/2012 |
Anciens postes connus de Madiha Derouazi
| Sociétés | Poste | Fin |
|---|
Formation de Madiha Derouazi
| Technical University of Berlin | Graduate Degree |
| Swiss Federal Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Entreprise privées | 1 |
|---|---|
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
